Tag: source

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $3.15 billion in global CTV open programmatic ad spend is routed through unauthorized sellers; 9% of mobile in-app traffic with SCOs marked as ‘complete’ was sold by unauthorized direct sellers

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $652 million in global CTV open programmatic ad spend is routed through unauthorized sellers; 28% of Connected TV (CTV) traffic with SCOs marked as ‘complete’ was sold by unauthorized direct sellers

LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”) announced today that it has received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) wherein, based on the Company’s Form 6-K, dated June 26, 2025, Nasdaq has determined that the Company complies with the Listing Rule 5550(b)(1).

PASCAGOULA, Miss., July 01, 2025 (GLOBE NEWSWIRE) --  HII’s (NYSE: HII) Ingalls Shipbuilding division recently concluded its third annual educator externship, hosting 15 educators from school districts across the Mississippi Gulf Coast. The two-week program, held June 9-20, is part of HII’s broader initiative to strengthen skilled workforce pipelines and align local education efforts with national defense needs.

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030. Is it a fair deal?